Japan Cell Therapy Market Size & Outlook, 2023-2030
Related Markets
Japan cell therapy market highlights
- The Japan cell therapy market generated a revenue of USD 162.4 million in 2023 and is expected to reach USD 699.2 million by 2030.
- The Japan market is expected to grow at a CAGR of 23.2% from 2024 to 2030.
- In terms of segment, autologous therapies was the largest revenue generating therapy type in 2023.
- Allogeneic Therapies is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell therapy market data book summary
| Market revenue in 2023 | USD 162.4 million |
| Market revenue in 2030 | USD 699.2 million |
| Growth rate | 23.2% (CAGR from 2023 to 2030) |
| Largest segment | Autologous therapies |
| Fastest growing segment | Allogeneic Therapies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Allogeneic Therapies, Autologous Therapies |
| Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, Japan accounted for 3.4% of the global cell therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, South Korea cell therapy market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 103.7 million by 2030.
Key Regions: U.S. , UK , Canada , Germany , Switzerland
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Therapy Market Scope
Cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Nkarta Inc Ordinary Shares | View profile | 150 | 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080 | https://www.nkartatx.com |
| Atara Biotherapeutics Inc | View profile | 173 | 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, United States, 91320 | https://www.atarabio.com |
| JW (Cayman) Therapeutics Co Ltd Ordinary Shares | View profile | 398 | No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, China, People's Republic of | https://www.jwtherapeutics.com |
| Medipost | View profile | 51-100 | Seongnam, Kyonggi-do, South Korea, Asia | http://www.medi-post.com/ |
| JCR Pharmaceuticals Co Ltd | View profile | 932 | 3-19 Kasuga-cho, Ashiya, Hyogo, Japan, 659-0021 | http://www.jcrpharm.co.jp |
| Gilead Sciences Inc | View profile | 18000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | https://www.gilead.com |
| Beiersdorf AG | View profile | 21958 | Unnastrasse 48, Hamburg, Germany, 22529 | https://www.beiersdorf.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Japan cell therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy market will help companies and investors design strategic landscapes.
Autologous therapies was the largest segment with a revenue share of 83.19% in 2023. Horizon Databook has segmented the Japan cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The cell therapy market in Japan is driven by several initiatives undertaken by Japanese companies to increase access to cell therapies, coupled with the rising approvals & clinical trials for cell-based therapies, in the country.
For instance, in February 2023, Novo Nordisk A/S and Heartseed, Inc. achieved a significant milestone by administering the first dose to a patient in the phase 1/2 clinical study, known as the LAPiS Study, for HS-001 an investigational cell therapy targeting heart failure.
The clinical phase 1/2 of the LAPiS Study would enroll 10 individuals with advanced heart failure caused by an ischemic heart condition. Thus, such clinical studies & trials for various cell therapies targeting numerous conditions like cardiovascular disease and cancer are expected to boost the competition in the Japan cell therapy market.
Reasons to subscribe to Japan cell therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan cell therapy market databook
-
Our clientele includes a mix of cell therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into Japan cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan cell therapy market size, by allogeneic therapies, 2018-2030 (US$M)
Japan Cell Therapy Market Outlook Share, 2023 & 2030 (US$M)
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
